ClinicalTrials.gg
CompletedNCT05154240Updated Jun 29, 2023

A Phase 1, Evaluate the Safety, Tolerability, and Pharmacokinetics of INS018_055 in Healthy Subjects

A Phase 1 interventional study of INS018_055 and Placebo in Idiopathic Pulmonary Fibrosis, sponsored by InSilico Medicine Hong Kong Limited. Completed at 1 site in New Zealand. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-06-29.

Sponsored by InSilico Medicine Hong Kong Limited · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies in Idiopathic Pulmonary Fibrosis with a site in New Zealand — 4 open to participants now, 6 under way, 2 of them phase 3. Idiopathic Pulmonary Fibrosis · New Zealand.

Enrollment
19th of 21
78 · median 286
Started
2022
with 3 others
Phase 1
Only one
of the 21
Registered
9th of 21
by date

Among the 21 studies in Idiopathic Pulmonary Fibrosis with a site in New Zealand, this one is the 19th largest by enrollment, is one of 4 that started in 2022, is the only one in phase 1, and was the 9th registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

4 of the 21 studies in Idiopathic Pulmonary Fibrosis with a site in New Zealand are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in New Zealand have not opened yet or have stopped. Only those recruiting at a site in New Zealand →

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Idiopathic Pulmonary Fibrosis with a site in New Zealand, or all of them as a file.
02

Study summary

The sponsor is planning to conduct a Phase 1, randomized, double-blind, placebo-controlled, oral single and multiple ascending-doses, parallel group study to evaluate the safety, tolerability and PK of INS018_055 in healthy subjects. The study will be conducted in 1 clinical site in the New Zealand, consisting of 2 parts: Part A (single ascending dose [SAD]) and Part B (multiple ascending dose [MAD]).

Read the detailed description

This is a Phase 1, randomized, 2-part (Part A and B), double-blind, placebo controlled single and multiple ascending doses study designed to assess the safety, tolerability, and PK of INS018_055 when administered as oral doses to healthy subjects. Additionally, this study will investigate the impact of food on the PK of INS018_055.

Part A (Single Ascending Dose [SAD]):

Eight healthy subjects will be assigned to each of up to 5 sequential dose cohorts and will be randomly assigned within each dose cohort to receive INS018_055 or a matched placebo in a ratio of 3:1 (6 active, 2 placebo) on Day 1 for a total of up to approximately 40 subjects. Subjects in Part A will be admitted to the study site on Day -1 and dosed on Day 1 after fasting (nothing to eat or drink, except water) for at least 10 hours. Water is not allowed 1 hour prior to and 1 hour after dosing. Water can be consumed ad libitum at other times. Subjects will remain fasted on Day 1 for 4 hours after dosing. Subjects will be discharged from the study site on Day 4, after the scheduled procedures and review of the Day 4 safety data by the investigator (or designee). Subjects will come back for an end of study (EOS) visit on Day 8 (± 1 day).

A sentinel cohort of 2 subjects will be used to mitigate the risk of unexpected adverse events (AEs) not predicted by preclinical pharmacology and toxicology studies for each dosing cohort, starting with Cohort 1 (the initial dose cohort). The sentinel subjects will be dosed in a blinded fashion (1 active, 1 placebo) and monitored for at least 1 day before the remaining 6 subjects in that cohort are dosed. Initiation of dosing of the remaining 6 subjects will depend on an initial safety review by the investigator indicating that administration of the study treatment was safe and well tolerated in the sentinel subjects.

Dose escalation will occur only after the real time PK, safety, and tolerability data (including reported AEs, physical examinations, vital signs, electrocardiograms (ECGs), and clinical laboratory results up to 48 hours after dosing) of the preceding dose cohort for at least 6 subjects are assessed and the study treatment is deemed safe and well tolerated by the safety review committee (SRC). As new safety and/or PK data become available, the anticipated dose escalation scheme may change following a review of the data by the SRC. Preliminary PK data from subjects in this study will help guide dose escalation to higher doses. Dose escalation in Cohorts 4 and 5 will only occur after the PK data from at least the first 2 cohorts have been assessed and deemed sufficient to model exposures for Cohorts 4 and 5.

Food Effect Assessment (Cohort 4 in Part A only): Subjects in Cohort 4 of Part A will participate in a food effect arm. The actual dose level for food effect cohort is subject to change and will be confirmed by the SRC after review of data from at least the first 2 cohorts of the SAD. Following the standard SAD dosing on Day 1 and at least 3 days of follow up/washout (or 5 times the estimated half-life of INS018_055 based on the observed data, whichever is longer) (Period 1), enrolled subjects will enter Period 2 and be re administered the same dose of INS018_055 or matching placebo (the same treatment that they received on Day 1 of Period 1) after completing a standard high-fat meal. Subjects will fast (nothing to eat and drink, except water) for at least 10 hours overnight and receive a standard high-fat breakfast 30 minutes prior to dosing. The high-fat breakfast will be consumed within approximately 30 minutes. Subjects will remain at the study site on Day 4 of Period 2 until the scheduled procedures and review of the Day 4 safety data by the investigator (or designee) are completed. The washout period of at least 3 days (or 5 times the estimated half life of INS018_055 based on the observed data, whichever is longer) may be extended based on available PK data from previous cohorts. The Day -1 procedures will not be repeated for Period 2.

Physical examinations, vital sign measurements, 12-lead ECGs, and clinical laboratory evaluations will be performed at selected time points throughout the study. Subjects will also be closely monitored for AEs throughout the study. Blood samples for PK will be collected up to 72 hours after study treatment administration on Day 1 for all cohorts. For biomarkers (CD4+ and CD8+ T-cells), blood samples will be collected at check-in (Day -1), Day 2, and Day 4 after administration of INS018_055. Fecal occult blood tests will be done with all stools passed at screening, check-in (Day -1), and during the 72 hour observation period. Subjects will be discharged on Day 4.

Part B (Multiple Ascending Dose [MAD]):

Eight healthy subjects will be assigned to each of up to 5 sequential once daily (QD) or twice daily (BID) dose cohorts and will be randomly assigned within each dose cohort to receive INS018_055 or a matched placebo for 10 days in a ratio of 3:1 (6 active, 2 placebo), for a total of up to approximately 40 subjects.

Subjects in Part B will begin dosing, after safety and tolerability data (including reported AEs, physical examination, clinical laboratory results, 12-lead ECGs, and vital signs) from at least the first 3 cohorts (Cohorts 1 to 3) in Part A are assessed and the study treatment is deemed safe and well tolerated by the SRC. Additionally, sufficient PK data from at least the first 3 cohorts of Part A must be obtained to model exposures in Part B. The dosing schedule, either QD or BID, will be decided by the SRC after review of the PK, safety, and tolerability data from the first 3 cohorts of Part A.

The initial MAD cohorts will begin dosing with the remaining SAD cohorts. The top dose explored in Part B will not exceed the maximum dose explored in Part A. Subsequent dose escalations in Part B will not occur until the safety (including AEs, physical examination, clinical laboratory results, vital signs, and 12-lead ECGs) and tolerability data up to and including Day 14 of the preceding MAD dose cohort for at least 6 subjects are assessed and the study treatment is deemed safe by the SRC.

As new safety or PK data become available, the dose escalation scheme may change. Subjects may not receive a subsequent higher dose and may instead be administered a lower dose or may repeat the same daily dose with a different administration schema, eg, BID instead of QD dosing, to achieve lower maximum observed plasma concentration (Cmax) values, particularly if the safety findings are believed to be linked to the Cmax values.

The highest dose in the MAD (either QD or BID) will be dosed in a staggered way if accrued PK data from previous cohorts predict potential exposures above the no observed adverse effect level, with 2 subjects starting dosing at least 7 days before the remaining 6 subjects; initiation of dosing of the remaining 6 subjects will depend on an initial safety review by the investigator indicating that administration of the study treatment was safe and well tolerated in the sentinel subjects.

Each subject in Part B will be admitted to the study site on Day -1 and will begin daily dosing on Day 1. Study treatment is to be administered daily at approximately the same time in the morning. For BID dosing, the second dose of study treatment will be administered approximately 12 hours after the morning dose of study treatment.

Prior to the morning dosing on Days 1 and 10 for Cohorts 6 to 10, subjects will fast (nothing to eat and drink, except water) for at least 10 hours overnight and remain fasted for 4 hours after study treatment administration. Water is not allowed 1 hour prior to and 1 hour after dosing. Water can be consumed ad libitum at other times. Water is not restricted for the evening doses when study treatment is being dosed BID. On Days 1 and 10, lunch will be provided approximately 4 hours after the morning dose, dinner will be provided approximately 10 hours after the morning dose, and a snack will be provided approximately 13 hours after the morning dose.

On Days 2 to 9 for Cohorts 6 to 10, breakfast will be provided approximately 60 minutes after study treatment administration. Standardized meals will be provided to the subjects throughout the study. Lunch will be provided approximately 4 hours after the morning dose, dinner will be provided approximately 10 hours after the morning dose, and a snack will be provided approximately 13 hours after the morning dose.

Physical examinations, vital sign measurements, 12-lead ECGs, and clinical laboratory evaluations (including liver function test results) will be performed at selected time points throughout the dosing interval. Subjects will be closely monitored for AEs throughout the study. Blood samples for PK analyses will be collected up to 72 hours after study treatment administration on Day 10. Urine samples for PK analysis will be collected before dosing (Day 1 as a single void collected within 0 to 24 hours) and over the following intervals after dosing: 0 to 4, 4 to 8, 8 to 12, and 12 to 24 hours on Day 1 and 0 to 4, 4 to 8, 8 to 12, 12 to 24, and 24 to 48 hours on Day 10 for both QD and BID cohorts. For biomarkers (CD4+ and CD8+ T-cells), blood samples will be collected at selected time points for QD and BID dosing cohorts. Fecal occult blood tests will be done with all stool samples at screening, check-in (Day 1), and throughout Part B on site observation periods, ie, up to Day 14.

Subjects will be discharged from the study site on Day 14, after the scheduled procedures and review of the safety data by the investigator (or designee). Subjects will return to the study site on Day 28 (± 3 days) for an EOS visit.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis

Keywords

  • IPF
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject is a male or female 18 to 55 years of age, inclusive.
  2. The subject has a 18 to 32 kg/m2, inclusive, and a total body weight ≥50 kg, inclusive, at screening.
  3. The subject is considered by the investigator to be in good general health as determined by medical history, clinical laboratory test results, vital sign measurements, 12-lead results, and physical examination findings at screening.
  4. Female subjects of must be non-pregnant and non-lactating and must use one of the methods of listed below for the duration of the treatment until at least 28 days after the last dose of the study drug, or be surgically sterile (ie, hysterectomy, bilateral tubal ligation, or bilateral oophorectomy), or (defined as amenorrhea 12 consecutive months and documented plasma follicle stimulating hormone level >40 IU/mL). Female subjects must have a negative pregnancy test at screening and before the first dose of study drug.

    Highly effective methods of contraception are those that result in a failure rate of less than 1% per year when used consistently. Examples are provided below:

    1. Implant contraceptive (eg, Jadelle®)
    2. Intrauterine device containing either copper or levonorgestrel (eg, Mirena®)
    3. Male sterilization with absence of sperm in the post-vasectomy ejaculate

      OR an effective method that result in a failure rate of less than 5% to 10% per year. Examples are provided below:

    4. Injectable contraceptive (eg, Depo Provera)
    5. Oral contraceptive pill (combined hormonal contraceptive pill or progestogen-only 'mini-pill')
    6. Vaginal contraceptive ring (eg, NuvaRing®)

    Female subjects must also agree not to donate eggs, from dosing until at least 28 days after the last dose of study drug.

    A male subject and his female partner who is of childbearing potential must agree to use one of the methods of contraception listed above for the duration of the treatment until at least 28 days after the last dose of the study drug. A male subject must also agree not to donate sperm, for the duration of the treatment until at least 28 days after the last dose of the study drug.

  5. The subject agrees to comply with all protocol requirements.
  6. The subject is able to provide written .

Exclusion criteria

Exclusion Criteria:

  1. The subject has current evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
  2. The subject has any condition possibly affecting drug absorption (eg, gastrectomy).
  3. The subject has a history of cancer with the exception of adequately treated basal cell or squamous cell carcinoma of the skin.
  4. The subject has supine blood pressure (BP) >140 mm Hg (systolic) or >90 mm Hg (diastolic), following at least 5 minutes of supine rest. If BP is >140 mm Hg (systolic) or >90 mm Hg (diastolic), the BP should be repeated 2 more times and the average of the 3 BP values should be used to determine the subject's eligibility at screening.
  5. The subject has 12-lead demonstrating interval by Fridericia (QTcF) >450 msec, or a QRS interval >120 msec at screening. If QTcF exceeds 450 msec, or QRS interval exceeds 120 msec, the ECG should be repeated 2 more times and the average of the 3 QTcF (or QRS interval) values should be used to determine the subject's eligibility.
  6. The subject has ANY of the following abnormalities in clinical laboratory tests at screening, as assessed by the study-specific laboratory and confirmed by a single repeat, if deemed necessary:

    1. Serum creatinine level above the (ULN) or an estimated value \<80 mL/min/1.73 m2 calculated with the Chronic Kidney Disease Epidemiology Collaboration formula and the absence of protein in urine, at screening.
    2. or alanine aminotransferase values more than >1.5 × ULN.
    3. Fasting glucose >110 mg/dL (6.1 mmol/L).
    4. Total >1.5 × ULN.
    5. Hematological values outside the normal reference range for local laboratory results.
    6. Positive fecal occult blood test at screening or at check-in (Day -1).
  7. The subject has any medical history of disease that has the potential to cause a rise in total bilirubin over the ULN. Subjects with borderline clinical laboratory values outside the reference range may be included in the study if the investigator deems that the values are not clinically significant.

    Note: Subjects with a history of Gilbert's syndrome may have a direct bilirubin measured and would be eligible for this study provided the direct bilirubin is \<ULN.

  8. The subject has a history of any lymphoproliferative disorder (such as Epstein Barr Virus related lymphoproliferative disorder, as reported in some subjects on drugs), history of lymphoma, leukemia, myeloproliferative disorders, multiple myeloma, or signs and symptoms suggestive of current lymphatic disease.
  9. The subject has a history of relevant drug and/or food allergies (ie, allergy to any study drug or , or any significant food allergy that could preclude a standard diet in the clinical unit).
  10. The subject has a clinically significant infection currently or within 6 months of first dose of study drug (eg, those requiring hospitalization or parenteral antimicrobial therapy or opportunistic infections within the last 6 months), or a history of chronic or recurrent infectious disease.
  11. The subject has other severe acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
  12. The subject has or has had symptomatic herpes zoster or herpes simplex within 12 weeks, more than one episode of local herpes zoster, or a history (single episode) of disseminated zoster.
  13. The subject has a positive test result for surface antigen, virus antibody, or types 1 or 2 antibodies at screening.
  14. The subject is a female who is pregnant or lactating.
  15. The subject is a fertile male who is unwilling or unable to use a highly effective method of as outlined in this protocol for the duration of the study and for at least 28 days after the last dose of investigational product.
  16. The subject is unwilling or unable to comply with the lifestyle restrictions described in this protocol.
  17. The subject is a smoker or has used nicotine or nicotine-containing products (eg, snuff, nicotine patch, nicotine chewing gum, mock cigarettes, or inhalers) within 6 months before the first dose of study drug.
  18. The subject has a positive test result for drugs of abuse, or cotinine (indicating active current smoking) at screening or before the first dose of study drug.
  19. The subject has used any prescription or over the counter medications (except paracetamol [up to 2 g per day]), including herbal supplements, within 14 days before the first dose of study drug. Nutritional supplements are allowed if unlikely to interfere with the study results and agreed by medical monitor and investigator.
  20. The subject has consumed grapefruit or grapefruit juice, Seville orange or Seville orange containing products (eg, marmalade), or alcohol-, caffeine-, or xanthine containing products within 48 hours before the first dose of study drug.
  21. The subject will have vaccination with live virus, attenuated live virus, or any live viral components within 2 weeks prior to the first dose of study drug or is to receive these vaccines at any time during treatment or within 8 weeks following completion of study treatment.
  22. The subject has a positive test result for severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2). The subject has received the Coronavirus disease 2019 (COVID-19) vaccine within 2 weeks prior to the first dose of study drug or plans to receive a COVID-19 vaccine within 12 weeks after study drug dosing or has positive test for SARS CoV 2 during screening or presence of COVID 19 symptoms within 4 weeks prior to Day -1.
  23. The subject has undergone significant trauma or major surgery within 4 weeks of screening.
  24. The subject has bleeding risk: genetic predisposition to bleeding, a hemorrhagic event in the 12 months before the start of screening, or abnormal laboratory coagulation parameters.
  25. The subject has a first-degree relative with a hereditary immunodeficiency.
  26. The subject has investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or subjects who are sponsor employees including their family members are directly involved in the conduct of the study.
  27. The subject has a history of alcohol abuse or drug addiction within the last year or excessive alcohol consumption (regular alcohol intake >21 units per week for male subjects and >14 units of alcohol per week for female subjects) (1 unit is equal to approximately ½ pint [200 mL] of beer, 1 small glass [100 mL] of wine, or 1 measure [25 mL] of spirits) or use of alcohol 48 hours before the first dose of study drug.
  28. The subject is involved in strenuous activity or contact sports within 24 hours before dosing and during the study.
  29. The subject has donated blood or blood products >450 mL within 30 days before the first dose of study drug.
  30. The subject has received study drug in another investigational study within 30 days of dosing.
  31. The subject received cytochrome P450 (CYP)/ multidrug and toxin extrusion (MATE) classes of medications within 4 weeks of first dose of INS018_055 or was likely to receive CYP/MATE classes of medications during the study.
  32. In the opinion of the investigator, the subject is not suitable for entry into the study.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
78 participants (actual)

Study arms

  • Active comparator
    INS018_055

    oral doses of INS018_055_single dose; oral doses of INS018_055_multiple ascending dose over 10days.

    Drug: INS018_055

  • Placebo comparator
    Placebo

    No active ingredient. Frequency similar to the 2 arms above.

    Drug: Placebo

Interventions

  • INS018_055 is a small molecule compound. INS018_055 has good solubility in water and was chemically and physically stable at different temperatures.

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Number of participants with treatment-related adverse events based on subjective and objective examination

    Subjective examination refers to the participant response to standard question to elicit any medically related changes in their well-being. Descriptive examination refers to laboratory values as reviewed by the investigator, physical examination findings and ECG Changes, or other documents that are relevant to participant safety. AEs will be classified as: Mild: These events require minimal or no treatment and do not interfere with the subject's daily activities. Moderate: These events result in a low level of inconvenience or require minor therapeutic measures. Moderate events may cause some interference with normal functioning. Severe: These events interrupt a subject's usual daily activity and may require systemic drug therapy or other treatment. Severe events are usually incapacitating.

    Time frame: 12 months

Secondary outcomes

  1. Maximum Plasma Concentration [Cmax]

    * To determine the PK of INS018_055 following single and multiple oral escalating doses in healthy subjects. * To assess the effect of food on the PK of INS018_055 following an oral dose.

    Time frame: 12 months

  2. Area under the plasma concentration versus time curve (AUC) from time 0 to the last quantifiable concentration (AUC0-t)

    * To determine the PK of INS018_055 following single and multiple oral escalating doses in healthy subjects. * To assess the effect of food on the PK of INS018_055 following an oral dose.

    Time frame: 12 months

  3. AUC from time 0 extrapolated to infinity (AUC0-inf)

    * To determine the PK of INS018_055 following single and multiple oral escalating doses in healthy subjects. * To assess the effect of food on the PK of INS018_055 following an oral dose.

    Time frame: 12 months

  4. AUC from time 0 to the time of the dosing interval (To; AUC0-To)

    * To determine the PK of INS018_055 following single and multiple oral escalating doses in healthy subjects. * To assess the effect of food on the PK of INS018_055 following an oral dose.

    Time frame: 12 months

  5. Accumulation ratio (AR), calculated as AUC0-To (Day 10)/AUC0-To (Day 1)

    * To determine the PK of INS018_055 following single and multiple oral escalating doses in healthy subjects. * To assess the effect of food on the PK of INS018_055 following an oral dose.

    Time frame: 12 months

  6. AR calculated as Cmax (Day 10)/Cmax (Day 1)

    * To determine the PK of INS018_055 following single and multiple oral escalating doses in healthy subjects. * To assess the effect of food on the PK of INS018_055 following an oral dose.

    Time frame: 12 months

  7. Time to reach Cmax (Tmax)

    * To determine the PK of INS018_055 following single and multiple oral escalating doses in healthy subjects. * To assess the effect of food on the PK of INS018_055 following an oral dose.

    Time frame: 12 months

  8. Pre-dose concentrations on Days 1 through 10 (C trough)

    * To determine the PK of INS018_055 following single and multiple oral escalating doses in healthy subjects. * To assess the effect of food on the PK of INS018_055 following an oral dose.

    Time frame: 12 months

  9. Average concentration on Day 1 and Day 10 (Cav)

    * To determine the PK of INS018_055 following single and multiple oral escalating doses in healthy subjects. * To assess the effect of food on the PK of INS018_055 following an oral dose.

    Time frame: 12 months

  10. Terminal elimination rate constant (Kel)

    * To determine the PK of INS018_055 following single and multiple oral escalating doses in healthy subjects. * To assess the effect of food on the PK of INS018_055 following an oral dose.

    Time frame: 12 months

  11. Terminal elimination half-life (t1/2)

    * To determine the PK of INS018_055 following single and multiple oral escalating doses in healthy subjects. * To assess the effect of food on the PK of INS018_055 following an oral dose.

    Time frame: 12 months

  12. Apparent total body clearance (CL/F)

    * To determine the PK of INS018_055 following single and multiple oral escalating doses in healthy subjects. * To assess the effect of food on the PK of INS018_055 following an oral dose.

    Time frame: 12 months

  13. Peak to trough ratio calculated as Cmax/Ctrough

    * To determine the PK of INS018_055 following single and multiple oral escalating doses in healthy subjects. * To assess the effect of food on the PK of INS018_055 following an oral dose.

    Time frame: 12 months

  14. Apparent volume of distribution (Vd/F)

    * To determine the PK of INS018_055 following single and multiple oral escalating doses in healthy subjects. * To assess the effect of food on the PK of INS018_055 following an oral dose.

    Time frame: 12 months

  15. Metabolite-to parent ratio based on AUC calculated as AUCmetabolite/AUCparent

    * To determine the PK of INS018_055 following single and multiple oral escalating doses in healthy subjects. * To assess the effect of food on the PK of INS018_055 following an oral dose.

    Time frame: 12 months

  16. Metabolite-to parent ratio based on Cmax calculated as Cmax, metabolite/Cmax, parent

    * To determine the PK of INS018_055 following single and multiple oral escalating doses in healthy subjects. * To assess the effect of food on the PK of INS018_055 following an oral dose.

    Time frame: 12 months

  17. Renal clearance (CLr)

    * To determine the PK of INS018_055 following single and multiple oral escalating doses in healthy subjects. * To assess the effect of food on the PK of INS018_055 following an oral dose.

    Time frame: 12 months

  18. Total amount of drug excreted unchanged in urine from 0 to 24 hours after dosing (XU0-24)

    * To determine the PK of INS018_055 following single and multiple oral escalating doses in healthy subjects. * To assess the effect of food on the PK of INS018_055 following an oral dose.

    Time frame: 12 months

Other outcomes

  1. Characterisation of CD4+ and CD8+ subpopulation of T cells after single dose and of the same after multiple oral escalating doses of INS018_055

    To determine the effect of single doses of INS018_055 on the circulating CD4+ and CD8+ subpopulation of T cells and the effect of multiple oral escalating doses of INS018_055 on circulating CD4+ and CD8+ subpopulation of T cells as these could be used as biomarkers for the selection of the therapeutic dose range.

    Time frame: 12 months

07

Study locations

1 site
  • NZCR Ltd
    Christchurch, 8011, New Zealand
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2022 to primary completion in Dec 2022, 9 months.

Of 60 industry-sponsored phase 1 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 9 months is close to that.

Counting every sponsor, half of 75 studies reached it within 12 months; a quarter within 5 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2021
First posted
Dec 13, 2021
StartActual
Feb 21, 2022
Primary completionActual
Dec 2, 2022
CompletionActual
Dec 2, 2022
Last update
Jun 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05154240
Lead sponsor
InSilico Medicine Hong Kong Limited
Responsible party
Sponsor
First posted
Dec 13, 2021
Start date
Feb 21, 2022
Primary completion
Dec 2, 2022
Completion
Dec 2, 2022
Last update
Jun 29, 2023

Study contacts

Christopher J Wynne, MBChB
principal investigator · New Zealand Clinical Research

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rentosertib

Start the discussion